Belite Bio, Inc's (BLTE) CEO Tom Lin on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/13/22
Belite Bio Reports First Half 2022 Operational Highlights and Financial ResultsGlobeNewsWire • 08/11/22
Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial ResultsGlobeNewsWire • 08/01/22
Belite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt DiseaseGlobeNewsWire • 07/19/22
Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public OfferingGlobeNewsWire • 05/12/22
Belite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022GlobeNewsWire • 05/05/22